Paper Details

  1. Home
  2. Paper Details

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.

Author: BrümmendorfTim H, CortesJorge E, DokiNoriko, García-GutiérrezValentín, IshizawaKenichi, MatsumuraItaru, OhkuraMasayuki, OnoChiho, OnoTakaaki, RostiGianantonio, SakaidaEmiko, TakahashiNaoto, TanetsuguYusuke, ViqueiraAndrea

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This pooled analysis of seven clinical trials evaluated the safety of bosutinib, a tyrosine kinase inhibitor, in Japanese versus non-Japanese patients with chronic myeloid leukemia (CML). The study found that the safety profile of bosutinib was generally consistent between the two groups, with some differences in the incidence of gastrointestinal, liver function, and rash events. The study suggests that bosutinib is well-tolerated in Japanese patients and that dose modifications and supportive care can effectively manage adverse events.
Paper Details　
Original Abstract of the Article :
Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of seven Pfizer-sponsored clinical trials evaluated the safety of bosutinib in Japanese (n = 138) vs non-Japanese (n = 1210) patients with CML. Fi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12185-022-03314-y

データ提供：米国国立医学図書館（NLM）

Bosutinib: A Safe and Effective Treatment for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that requires long-term treatment. This research evaluates the safety profile of bosutinib, a tyrosine kinase inhibitor, in Japanese and non-Japanese patients with CML.

Bosutinib: A Global Treatment Approach

The study found that the safety profile of bosutinib in Japanese patients was generally consistent with that in non-Japanese patients, despite some differences in the incidence of specific side effects. This suggests that bosutinib can be safely and effectively used to treat CML patients globally.

Managing Side Effects: A Collaborative Effort

The study highlights the importance of proactive side effect management in patients receiving bosutinib treatment. Dose modifications and supportive care can effectively address potential adverse events, ensuring optimal treatment outcomes for CML patients. This research underscores the importance of a collaborative approach between healthcare professionals and patients to navigate the challenges of long-term cancer treatment.

Dr.Camel's Conclusion

Imagine a camel caravan carrying precious cargo across a vast desert. CML, like the desert, presents its own unique challenges for patients. Bosutinib, like a skilled caravan leader, helps navigate these challenges, offering a safe and effective treatment option. This study reminds us that careful management of side effects is essential, just as a caravan leader ensures the well-being of the animals and their cargo.

Date :
  1. Date Completed 2022-06-03
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

35235189

DOI: Digital Object Identifier

10.1007/s12185-022-03314-y

Related Literature

Article Analysis
・Effects of bosutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.